A Multiple-Dose Study of Intravenous BNZ132‑1-40 in Healthy Adult Subjects

Trial Profile

A Multiple-Dose Study of Intravenous BNZ132‑1-40 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2018

At a glance

  • Drugs BNZ 1 (Primary)
  • Indications Alopecia areata; T-cell leukaemia; Tropical spastic paraparesis
  • Focus Adverse reactions
  • Sponsors Bioniz
  • Most Recent Events

    • 12 May 2018 Status changed from active, no longer recruiting to completed.
    • 01 May 2018 According to a Bioniz media release, full results will be at the 2018 International Investigative Dermatology Meeting.
    • 01 May 2018 Results presented in a Bioniz Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top